Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Clin Exp Nephrol ; 17(4): 569-74, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23224027

RESUMO

BACKGROUND: The development of erythropoiesis-stimulating agents (ESAs) with extended serum half-lives has allowed marked prolongation of the administration intervals. The level of oxidative stress is increased in chronic kidney disease, and is reportedly decreased after long-term ESA treatment. However, the effect of different dosing regimens of ESAs on oxidative stress has not been elucidated. METHODS: Five-sixths nephrectomized (NX) rats received either 0.4 µg/kg darbepoetin alfa (DA) weekly or 0.8 µg/kg DA fortnightly between weeks 4 and 10. NX animals receiving saline and a sham-operated (SHAM) group served as controls. The levels of oxidized and reduced glutathione (GSSG, GSH) were followed from blood samples drawn fortnightly. RESULTS: During the follow-up, the ratios GSSG/GSH showed similar trends in both DA groups, levels being significantly lower than those in the SHAM group at weeks 8 and 10. GSSG levels were lower than the baseline throughout the study in all groups except for NX controls. The GSH levels were increased in all three NX groups (weeks 6-10) compared with both the baseline and the SHAM group CONCLUSION: Our results suggest that the extent of oxidative stress is similar in response to different dosing regimens of DA in 5/6 NX rats when comparable hemoglobin levels are maintained. These findings remain to be confirmed in chronic kidney disease patients.


Assuntos
Eritropoetina/análogos & derivados , Dissulfeto de Glutationa/sangue , Glutationa/sangue , Hematínicos/administração & dosagem , Animais , Darbepoetina alfa , Esquema de Medicação , Eritropoetina/administração & dosagem , Masculino , Nefrectomia , Estresse Oxidativo , Ratos
2.
Life Sci ; 91(19-20): 907-11, 2012 Nov 02.
Artigo em Inglês | MEDLINE | ID: mdl-22982469

RESUMO

AIM: Oxidative stress, observed in the asthmatic airways, is not localized only to the bronchial system. It would be a great advantage to monitor the oxidative stress markers from blood especially in childhood asthma following the inflammation. Our aim was to measure the levels of antioxidants and the oxidatively damaged biomolecules. We were also interested in the gene expression alterations of the free radical source gp91(phox) subunit (CYBB) of the NADPH oxidase system, and the antioxidant heme oxygenase-1 (HMOX-1) isoenzyme in the blood. Our findings were also examined in the context of medical treatment. MAIN METHODS: Oxidative stress parameters via photometric methods, CYBB and HMOX-1 expressions via real-time PCR were measured in 58 asthmatic and 30 healthy children. KEY FINDINGS: Higher blood thiobarbituric acid reactive substances (TBARS) (p<0.03) and carbonylated protein (p<0.05) levels were found in the asthmatic children than in the controls. The relative expression of CYBB was significantly lower (p<0.05) in patients treated with a low daily dose of inhaled corticosteroid (ICS), than in asthmatics not receiving ICS therapy. Higher ICS doses alone or combined with long acting ß2-receptor agonists did not influence the expression significantly. No similar tendency was found as regards to HMOX-1 expression. SIGNIFICANCE: Elevated levels of damaged lipid (TBARS) and protein (carbonylated) products corroborate the presence of oxidative stress in the blood during bronchial asthma and suggest the presence of chronic oxidative overload. Our findings also suggest that ICS treatment can influence the relative CYBB mRNA expression in circulating leukocytes in a dose dependent manner.


Assuntos
Asma/tratamento farmacológico , Glucocorticoides/farmacologia , Glicoproteínas de Membrana/metabolismo , NADPH Oxidases/metabolismo , Estresse Oxidativo , Administração por Inalação , Adolescente , Agonistas de Receptores Adrenérgicos beta 2/administração & dosagem , Agonistas de Receptores Adrenérgicos beta 2/farmacologia , Agonistas de Receptores Adrenérgicos beta 2/uso terapêutico , Estudos de Casos e Controles , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Feminino , Regulação da Expressão Gênica , Glucocorticoides/administração & dosagem , Glucocorticoides/uso terapêutico , Heme Oxigenase-1/genética , Heme Oxigenase-1/metabolismo , Humanos , Leucócitos/metabolismo , Masculino , Glicoproteínas de Membrana/genética , NADPH Oxidase 2 , NADPH Oxidases/genética , Reação em Cadeia da Polimerase , Carbonilação Proteica , RNA Mensageiro/metabolismo , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo
3.
Mol Cell Probes ; 25(1): 28-34, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20951199

RESUMO

The Col4A3, Col4A4 and Col4A5 collagen type IV genes are found to be mutated in Col IV nephropathy. In males with a mutation in the Col4A5 gene (X-linked Alport syndrome: XL-AS), progressive renal disease always develops. Female carriers with a mutation in the Col4A5 gene can develop thin basement membrane nephropathy (TBMN). Males and females who carry 1 Col4A3 or Col4A4 mutation usually manifest TBMN with nonprogressive hematuria. In the event of 2 Col4A3 or Col4A4 gene mutations, the autosomal recessive AS will develop. We examined the cosegregation pattern of hematuria in 20 families. The renal biopsies led to diagnoses of AS in 7 families, and of TBMN in 6 families. In 7 others, the diagnosis of familial hematuria (FHU) was based on the clinical symptoms. Markers of the ColA3/Col4A4 and Col4A5 loci (Col4A3: CA11 and D2S401; Col4A4: HaeIII/RFLP; and Col4A5: DXS456, 2B6 and 2B20) were used to assess their linkage to the clinical symptoms and morphological alterations. Maximum likelihood and the FASTLINK version of the linkage program were applied to compute logarithm of the odds (LOD) scores. A linkage to the Col4A3/Col4A4 genes was identified in 5 families (FHU in 3, AS in 2 families, 25%, LOD score range: 0.20-3.51). The XL-AS pattern of inheritance seemed likely with Col4A5 in 9 families (45%, LOD: 0.43-4.20); we found 4 disease-causative mutations by high-resolution melting curve analysis (LC480) and sequencing in this group. In 2 FHU families, the linkage to chromosomes 2 and X was precluded. Knowledge of the genetic background of Col IV nephropathy is essential to avoid the misdiagnosis of FHU and early AS. The allele frequencies, heterozygosity content and polymorphism information content of the applied STR markers on unrelated Hungarian normal and affected chromosomes 2 and X were also calculated.


Assuntos
Colágeno Tipo IV/genética , Heterogeneidade Genética , Glomerulonefrite Membranosa/genética , Hematúria/genética , Nefrite Hereditária/genética , Adolescente , Adulto , Estudos de Casos e Controles , Criança , Cromossomos Humanos Par 2/genética , Cromossomos Humanos X/genética , Feminino , Genes Ligados ao Cromossomo X , Triagem de Portadores Genéticos , Ligação Genética , Marcadores Genéticos , Glomerulonefrite Membranosa/diagnóstico , Haplótipos , Hematúria/diagnóstico , Humanos , Masculino , Pessoa de Meia-Idade , Nefrite Hereditária/diagnóstico , Mutação Puntual , Polimorfismo de Fragmento de Restrição , Temperatura de Transição , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA